Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TNKS | O95271 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 5/20 | 0.39 |
| ▸ | HTR7 | P34969 | 5/20 | 0.39 |
| ▸ | HTR1A | P08908 | 4/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL542586 | 0.92 | LMNA (0.51) | MEN1KMT2ALMNATNKSMMP2 | |
| SCHEMBL17570773 | 0.92 | LMNA (0.51) | MEN1KMT2ALMNATNKSMMP2 | |
| SCHEMBL542522 | 0.78 | MEN1 (0.49) | MEN1KMT2ALMNATNKSMMP2 | |
| SCHEMBL542561 | 0.75 | LMNA (0.53) | MEN1KMT2ALMNATNKSMMP2 | |
| SCHEMBL20134878 | 0.75 | LMNA (0.53) | MEN1KMT2ALMNATNKSMMP2 | |
| SCHEMBL103835 | 0.74 | LMNA (0.56) | MEN1KMT2ALMNATNKSMMP2 | |
| SCHEMBL542817 | 0.74 | LMNA (0.51) | MEN1KMT2ALMNATNKSADAMTS5 | |
| SCHEMBL17054772 | 0.74 | MEN1 (0.55) | MEN1KMT2ALMNATNKSMMP2 | |
| SCHEMBL204119 | 0.74 | LMNA (0.51) | MEN1KMT2ALMNATNKSADAMTS5 | |
| SCHEMBL10131744 | 0.74 | LMNA (0.51) | MEN1KMT2ALMNATNKSMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153634-B2 | Carbinol derivatives having cyclic linker | KOWA COMPANY, LTD. (JP) | 2012-04-10 | — | — | US | disclosed |
| EP-2281817-A1 | SUBSTITUTED CARBINOL COMPOUND HAVING CYCLIC LINKER | Kowa Company, Ltd. (JP) | 2011-02-09 | — | — | EP | disclosed |
| US-20100048610-A1 | CARBINOL DERIVATIVES HAVING CYCLIC LINKER | KOWA COMPANY, LTD. (JP) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048610-A1 | CARBINOL DERIVATIVES HAVING CYCLIC LINKER | NR1H2, NR1H3, LDLR | MEN1 3823/4885KMT2A 2383/4885LMNA 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.